Ilaprazole

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ilaprazole
Accession Number
DB11964
Description

Ilaprazole has been investigated in Helicobacter Infections.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 366.44
Monoisotopic: 366.11504701
Chemical Formula
C19H18N4O2S
Synonyms
  • Ilaprazole
  • Ilaprazolum
External IDs
  • IY 81149
  • IY-81149
  • IY81149

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Alendronic acidThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Ilaprazole.
AmphetamineIlaprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
BudesonideIlaprazole can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Clodronic acidThe therapeutic efficacy of Clodronic acid can be decreased when used in combination with Ilaprazole.
DacomitinibIlaprazole can cause a decrease in the absorption of Dacomitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
DextroamphetamineIlaprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Etidronic acidThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Ilaprazole.
Ferrous sulfate anhydrousIlaprazole can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
FluconazoleThe metabolism of Ilaprazole can be decreased when combined with Fluconazole.
IbandronateThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Ilaprazole.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

International/Other Brands
Noltec

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzimidazoles
Sub Class
Sulfinylbenzimidazoles
Direct Parent
Sulfinylbenzimidazoles
Alternative Parents
Methylpyridines / Alkyl aryl ethers / Substituted pyrroles / Benzenoids / Imidazoles / Heteroaromatic compounds / Sulfoxides / Sulfinyl compounds / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
Alkyl aryl ether / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Ether / Heteroaromatic compound / Hydrocarbon derivative / Imidazole / Methylpyridine
show 13 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
776Q6XX45J
CAS number
172152-36-2
InChI Key
HRRXCXABAPSOCP-UHFFFAOYSA-N
InChI
InChI=1S/C19H18N4O2S/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23/h3-11H,12H2,1-2H3,(H,21,22)
IUPAC Name
2-[(4-methoxy-3-methylpyridin-2-yl)methanesulfinyl]-5-(1H-pyrrol-1-yl)-1H-1,3-benzodiazole
SMILES
COC1=C(C)C(CS(=O)C2=NC3=C(N2)C=CC(=C3)N2C=CC=C2)=NC=C1

References

General References
Not Available
PubChem Compound
214351
PubChem Substance
347828288
ChemSpider
185839
ChEBI
135544
ChEMBL
CHEMBL2106370
PharmGKB
PA165947499
Wikipedia
Ilaprazole

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedNot AvailableHelicobacter Infections1
4CompletedTreatmentDuodenal Ulcer Due to Helicobacter Pylori1
4CompletedTreatmentEradication Therapy of Helicobacter Pylori1
4CompletedTreatmentGastrointestinal Subepithelial Tumors / Upper Gastrointestinal Subepithelial Tumors1
4CompletedTreatmentHelicobacter Infections1
4CompletedTreatmentHelicobacter Pylori Eradication Antibiotic1
4CompletedTreatmentMalignant Neoplasm of Stomach1
4CompletedTreatmentPeptic Ulcer1
4Not Yet RecruitingTreatmentAntimicrobial Susceptibility Testing / Triple Therapy1
3CompletedTreatmentDuodenal Ulcer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0934 mg/mLALOGPS
logP2.42ALOGPS
logP3.04ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)10.1ChemAxon
pKa (Strongest Basic)4.27ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area72.8 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity111.91 m3·mol-1ChemAxon
Polarizability40.08 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 15:06 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates